The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes
10.3803/EnM.2019.34.2.106
- Author:
Gwang Sil KIM
1
;
Joong Hyun PARK
;
Jong Chul WON
Author Information
1. Department of Internal Medicine, Inje University Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea. drwonjc@gmail.com
- Publication Type:Review
- Keywords:
Diabetes mellitus;
Heart failure;
Hypoglycemic agents;
Myocardial ischemia
- MeSH:
Canagliflozin;
Cardiovascular Diseases;
Diabetes Mellitus;
Diabetes Mellitus, Type 2;
Glucagon-Like Peptide 1;
Glucose;
Heart Failure;
Humans;
Hyperglycemia;
Hypoglycemic Agents;
Liraglutide;
Mortality;
Myocardial Ischemia;
Prevalence;
Risk Factors
- From:Endocrinology and Metabolism
2019;34(2):106-116
- CountryRepublic of Korea
- Language:English
-
Abstract:
The prevalence of type 2 diabetes mellitus (T2DM), which is associated with cardiovascular morbidity and mortality, is increasing worldwide. Although there have been advances in diabetes treatments that reduce microvascular complications (nephropathy, neuropathy, retinopathy), many clinical studies have found that conventional oral hypoglycemic agents and glucose control alone failed to reduce cardiovascular disease. Thus, incretin-based therapies including glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2Is) represent a new area of research, and may serve as novel therapeutics for treating hyperglycemia and modifying other cardiovascular risk factors. Recently, it has been confirmed that several drugs in these classes, including canagliflozin, empagliflozin, semaglutide, and liraglutide, are safe and possess cardioprotective effects. We review the most recent cardiovascular outcome trials on GLP-1RAs and SGLT-2Is, and discuss their implications for treating patients with T2DM in terms of protective effects against cardiovascular disease.
